CoChat
Sign Up
Cited by 9Lipid metabolism and biosynthesisSphingolipid Metabolism and SignalingPeroxisome Proliferator-Activated Receptors

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

GDE7 produces cyclic phosphatidic acid in the ER lumen functioning as a lysophospholipid mediator

Open access
Kitakaze, Keisuke, Ali, Hanif, Kimoto, Raiki, Takenouchi, Yasuhiro, Ishimaru, Hironobu, Yamashita, Atsushi, Ueda, Natsuo, Tanaka, Tamotsu, Okamoto, Yasuo, Tsuboi, Kazuhito·2023·Communications Biology
DOI 10.1038/s42003-023-04900-4PMC PMC10188492

Published version of a preprint

Open this paper in CoChat — free accountOpen PDF

Abstract

Cyclic phosphatidic acid (cPA) is a lipid mediator, which regulates adipogenic differentiation and glucose homeostasis by suppressing nuclear peroxisome proliferator-activated receptor γ (PPARγ). Glycerophosphodiesterase 7 (GDE7) is a Ca 2+ -dependent lysophospholipase D that localizes in the endoplasmic reticulum. Although mouse GDE7 catalyzes cPA production in a cell-free system, it is unknown whether GDE7 generates cPA in living cells. Here, we demonstrate that human GDE7 possesses cPA-producing activity in living cells as well as in a cell-free system. Furthermore, the active site of human GDE7 is directed towards the luminal side of the endoplasmic reticulum. Mutagenesis revealed that amino acid residues F227 and Y238 are important for catalytic activity. GDE7 suppresses the PPARγ pathway in human mammary MCF-7 and mouse preadipocyte 3T3-L1 cells, suggesting that cPA functions as an intracellular lipid mediator. These findings lead to a better understanding of the biological role of GDE7 and its product, cPA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s42003-023-04900-4

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 62

  1. Tokumura, A. Metabolic pathways and physiological and pathological significances of lysolipid phosphate mediators. J. Cell. Biochem. 92, 869–881 (2004). · DOI
  2. Fujiwara, Y. Cyclic phosphatidic acid—a unique bioactive phospholipid. Biochim. Biophys. Acta 1781, 519–524 (2008). · DOI
  3. Geraldo, L. H. M. et al. Role of lysophosphatidic acid and its receptors in health and disease: Novel therapeutic strategies. Signal. Transduct. Target. Ther. 6, 45 (2021). · DOI
  4. Kano, K., Aoki, J. & Hla, T. Lysophospholipid mediators in health and disease. Annu. Rev. Pathol. 17, 459–483 (2022). · DOI
  5. Baker, D. L. et al. Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. J. Biol. Chem. 281, 22786–22793 (2006). · DOI
  6. Maeda-Sano, K. et al. Cyclic phosphatidic acid and lysophosphatidic acid induce hyaluronic acid synthesis via CREB transcription factor regulation in human skin fibroblasts. Biochim. Biophys. Acta 1841, 1256–1263 (2014). · DOI
  7. McIntyre, T. M. et al. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARγ agonist. Proc. Natl Acad. Sci. USA 100, 131–136 (2003). · DOI
  8. Tsukahara, T. et al. Phospholipase D2-dependent inhibition of the nuclear hormone receptor PPARγ by cyclic phosphatidic acid. Mol. Cell 39, 421–432 (2010). · DOI
  9. Forman, B. M. et al. 15-Deoxy-Δ12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83, 803–812 (1995). · DOI
  10. Kliewer, S. A. et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83, 813–819 (1995). · DOI · Paper page
  11. Tan, S. T., Ramesh, T., Toh, X. R. & Nguyen, L. N. Emerging roles of lysophospholipids in health and disease. Prog. Lipid Res. 80, 101068 (2020). · DOI
  12. Tsuda, S. et al. Cyclic phosphatidic acid is produced by autotaxin in blood. J. Biol. Chem. 281, 26081–26088 (2006). · DOI
  13. Bowling, F. Z., Frohman, M. A. & Airola, M. V. Structure and regulation of human phospholipase D. Adv. Biol. Regul. 79, 100783 (2021). · DOI
  14. Tsuboi, K. et al. Glycerophosphodiesterase GDE4 as a novel lysophospholipase D: a possible involvement in bioactive N-acylethanolamine biosynthesis. Biochim. Biophys. Acta 1851, 537–548 (2015). · DOI
  15. Ohshima, N. et al. New members of the mammalian glycerophosphodiester phosphodiesterase family: GDE4 and GDE7 produce lysophosphatidic acid by lysophospholipase D activity. J. Biol. Chem. 290, 4260–4271 (2015). · DOI
  16. Rahman, I. A. S. et al. Calcium-dependent generation of N-acylethanolamines and lysophosphatidic acids by glycerophosphodiesterase GDE7. Biochim. Biophys. Acta 1861, 1881–1892 (2016). · DOI
  17. Tserendavga, B. et al. Characterization of recombinant murine GDE4 and GDE7, enzymes producing lysophosphatidic acid and/or cyclic phosphatidic acid. J. Biochem. 170, 713–727 (2021). · DOI
  18. Kitakaze, K. et al. Development of a selective fluorescence-based enzyme assay for glycerophosphodiesterase family members GDE4 and GDE7. J. Lipid Res. 62, 100141 (2021). · DOI
  19. Su, W. et al. 5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis. Mol. Pharmacol. 75, 437–446 (2009). · DOI
  20. Lewis, J. A. et al. Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity. Bioorg. Med. Chem. Lett. 19, 1916–1920 (2009). · DOI
  21. Ferry, G. et al. S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool. J. Pharmacol. Exp. Ther. 327, 809–819 (2008). · DOI
  22. Jiang, G. et al. α-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA. ChemMedChem 2, 679–690 (2007). · DOI
  23. Tusnády, G. E. & Simon, I. The HMMTOP transmembrane topology prediction server. Bioinformatics 17, 849–850 (2001). · DOI
  24. Krogh, A., Larsson, B., Von Heijne, G. & Sonnhammer, E. L. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J. Mol. Biol. 305, 567–580 (2001). · DOI · Paper page
  25. Juretić, D., Zoranić, L. & Zucić, D. Basic charge clusters and predictions of membrane protein topology. J. Chem. Inf. Comput. Sci. 42, 620–632 (2002). · DOI
  26. López, G., Valencia, A. & Tress, M. L. firestar—prediction of functionally important residues using structural templates and alignment reliability. Nucleic Acids Res. 35, W573–W577 (2007). · DOI
  27. Yasuda, S., Nishijima, M. & Hanada, K. Localization, topology, and function of the LCB1 subunit of serine palmitoyltransferase in mammalian cells. J. Biol. Chem. 278, 4176–4183 (2003). · DOI
  28. Smith, T. F. & Waterman, M. S. Identification of common molecular subsequences. J. Mol. Biol. 147, 195–197 (1981). · DOI
  29. Li, Y. et al. PPAR-γ and Wnt regulate the differentiation of MSCs into adipocytes and osteoblasts respectively. Curr. Stem Cell Res. Ther. 13, 185–192 (2018). · DOI
  30. Bektas, M. et al. A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells. J. Cell Biol. 169, 801–811 (2005). · DOI
  31. Samadi, N., Gaetano, C., Goping, I. & Brindley, D. Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis. Oncogene 28, 1028–1039 (2009). · DOI
  32. Ortuno, V. E., Pulletikurti, S., Veena, K. S. & Krishnamurthy, R. Synthesis and hydrolytic stability of cyclic phosphatidic acids: implications for synthetic- and proto-cell studies. Chem. Commun. 58, 6231–6234 (2022). · DOI
  33. Fukasawa, K. et al. 2-Carba-lysophosphatidic acid is a novel β-lysophosphatidic acid analogue with high potential for lysophosphatidic acid receptor activation and autotaxin inhibition. Sci. Rep. 11, 17360 (2021). · DOI
  34. Steed, P. M., Clark, K. L., Boyar, W. C. & Lasala, D. J. Characterization of human PLD2 and the analysis of PLD isoform splice variants. FASEB J. 12, 1309–1317 (1998). · DOI
  35. Li, H. et al. Development and validation of a simple and rapid HILIC-MS/MS method for the quantification of low-abundant lysoglycerophospholipids in human plasma. Anal. Bioanal. Chem. 415, 411–425 (2023). · DOI
  36. Liu, P. et al. The mechanisms of lysophosphatidylcholine in the development of diseases. Life Sci. 247, 117443 (2020). · DOI · Paper page
  37. Kakisaka, K. et al. Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G77–G84 (2012). · DOI · Paper page
  38. Zheng, B., Berrie, C. P., Corda, D. & Farquhar, M. G. GDE1/MIR16 is a glycerophosphoinositol phosphodiesterase regulated by stimulation of G protein-coupled receptors. Proc. Natl. Acad. Sci. USA 100, 1745–1750 (2003). · DOI
  39. Aoyama, C. et al. Characterization of glycerophosphodiesterase 4-interacting molecules Gαq/11 and Gβ, which mediate cellular lysophospholipase D activity. Biochem. J. 476, 3721–3736 (2019). · DOI
  40. Uesugi, Y., Arima, J., Iwabuchi, M. & Hatanaka, T. C‐terminal loop of Streptomyces phospholipase D has multiple functional roles. Protein Sci. 16, 197–207 (2007). · DOI
  41. Fujiwara, Y. et al. Identification of residues responsible for ligand recognition and regioisomeric selectivity of lysophosphatidic acid receptors expressed in mammalian cells. J. Biol. Chem. 280, 35038–35050 (2005). · DOI
  42. Williams, J. R. et al. Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. J. Biol. Chem. 284, 17304–17319 (2009). · DOI
  43. Okuyama, K., Mizuno, K., Nittami, K., Sakaue, H. & Sato, T. Molecular mechanisms of cyclic phosphatidic acid-induced lymphangiogenic actions in vitro. Microvasc. Res. 139, 104273 (2022). · DOI
  44. Konakazawa, M., Gotoh, M., Murakami-Murofushi, K., Hamano, A. & Miyamoto, Y. The effect of cyclic phosphatidic acid on the proliferation and differentiation of mouse cerebellar granule precursor cells during cerebellar development. Brain Res. 1614, 28–37 (2015). · DOI
  45. Tsukahara, T., Hanazawa, S., Kobayashi, T., Iwamoto, Y. & Murakami-Murofushi, K. Cyclic phosphatidic acid decreases proliferation and survival of colon cancer cells by inhibiting peroxisome proliferator-activated receptor γ. Prostaglandins Other Lipid Mediat. 93, 126–133 (2010). · DOI
  46. Tsukahara, T. et al. Adenine nucleotide translocase 2, a putative target protein for 2-carba cyclic phosphatidic acid in microglial cells. Cell. Signal. 82, 109951 (2021). · DOI
  47. Augimeri, G. et al. The role of PPARγ ligands in breast cancer: from basic research to clinical studies. Cancers (Basel) 12, 2623 (2020). · DOI
  48. Shimizu, Y. et al. Hypoxia increases cellular levels of phosphatidic acid and lysophospholipids in undifferentiated Caco-2 cells. Lipids 58, 93–103 (2023). · DOI
  49. Naka, K. et al. The lysophospholipase D enzyme Gdpd3 is required to maintain chronic myelogenous leukaemia stem cells. Nat. Commun. 11, 4681 (2020). · DOI
  50. Key, C.-C. C. et al. Human GDPD3 overexpression promotes liver steatosis by increasing lysophosphatidic acid production and fatty acid uptake. J. Lipid Res. 61, 1075–1086 (2020). · DOI
  51. Beaulac, H. J., Gilels, F., Zhang, J., Jeoung, S. & White, P. M. Primed to die: an investigation of the genetic mechanisms underlying noise-induced hearing loss and cochlear damage in homozygous Foxo3-knockout mice. Cell Death Dis. 12, 682 (2021). · DOI
  52. Lew, A. R., Kellermayer, T. R., Sule, B. P. & Szigeti, K. Copy number variations in adult-onset neuropsychiatric diseases. Curr. Genomics. 19, 420–430 (2018). · DOI
  53. D’Angelo, C. S. & Koiffmann, C. P. Copy number variants in obesity-related syndromes: review and perspectives on novel molecular approaches. J. Obes. 2012, 845480 (2012).
  54. Thumser, A., Voysey, J. E. & Wilton, D. C. The binding of lysophospholipids to rat liver fatty acid-binding protein and albumin. Biochem. J. 301, 801–806 (1994). · DOI
  55. Kobayashi, T., Tanaka-Ishii, R., Taguchi, R., Ikezawa, H. & Murakami-Murofushi, K. Existence of a bioactive lipid, cyclic phosphatidic acid, bound to human serum albumin. Life Sci. 65, 2185–2191 (1999). · DOI
  56. Sekula, B., Ciesielska, A., Rytczak, P., Koziołkiewicz, M. & Bujacz, A. Structural evidence of the species-dependent albumin binding of the modified cyclic phosphatidic acid with cytotoxic properties. Biosci. Rep. 36, e00338 (2016). · DOI
  57. Stapleton, C. M. et al. Lysophosphatidic acid activates peroxisome proliferator activated receptor-γ in CHO cells that over-express glycerol 3-phosphate acyltransferase-1. PLoS ONE 6, e18932 (2011). · DOI
  58. Tsukahara, R., Haniu, H., Matsuda, Y. & Tsukahara, T. Heart-type fatty-acid-binding protein (FABP3) is a lysophosphatidic acid-binding protein in human coronary artery endothelial cells. FEBS Open Bio. 4, 947–951 (2014). · DOI
  59. Kitakaze, K. et al. ATF4-mediated transcriptional regulation protects against β-cell loss during endoplasmic reticulum stress in a mouse model. Mol. Metab. 54, 101338 (2021). · DOI
  60. Okamoto, Y. et al. Sphingosine 1-phosphate receptor type 2 positively regulates interleukin (IL)-4/IL-13-induced STAT6 phosphorylation. Cell. Signal. 88, 110156 (2021). · DOI
  61. Tokumura, A. et al. Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis. Int. J. Med. Sci. 6, 168–176 (2009). · DOI
  62. Takenouchi, Y., Kitakaze, K., Tsuboi, K. & Okamoto, Y. Growth differentiation factor 15 facilitates lung fibrosis by activating macrophages and fibroblasts. Exp. Cell Res. 391, 112010 (2020). · DOI

Metadata

Authors
Kitakaze, K., Ali, H., Kimoto, R., Takenouchi, Y., Ishimaru, H., Yamashita, A., Ueda, N., Tanaka, T., Okamoto, Y., & Tsuboi, K.
Affiliations
  • Kawasaki Medical School (JP)
  • Tokushima University (JP)
  • Teikyo University (JP)
  • Kagawa University (JP)
Corresponding author
  • Kitakaze, Keisuke
  • Tsuboi, Kazuhito
ORCID
Venue
Communications Biology
Publisher
Springer Science and Business Media LLC
Published
2023-05-16
Volume
6
Issue
1
Pages
524-524
ISSN
2399-3642 (ISSN-L)
DOI
10.1038/s42003-023-04900-4
PMC
PMC10188492
OpenAlex
W4376872782
Cited by
9
References
1
Citations by year
2025: 2 · 2024: 5 · 2023: 2
FWCI
0.91
Type
journal article
Language
en
Open access
Licence
Locations
  • Communications Biology (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Institutional Repositories DataBase (IRDB) (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
Funders
  • MEXT | Japan Society for the Promotion of Science (JP20K19732, JP20K11571)
  • Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care (2020-23)
  • Kyowa Hakko Kirin (KKCS20210402007 and KKCS20220401021)
  • Otsuka Pharmaceutical (AS2022A000441768)
  • Asahi Kasei Pharma Corporation (APJS20220406011)
  • Senko Medical Instrument Manufacturing Company (N/A)
  • Kawasaki Medical School (R01S-002, R02S-002, and R04Y-001)
  • Teijin Pharma (TJNS20200413014, TJNS20210412018, and TJNS20220411014)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Keywords
cyclic phosphatidic acid, autotaxin, endoplasmic reticulum lumen, PPARγ, adipogenesis, glucose homeostasis, active site residues, MCF-7 cells, 3T3-L1 preadipocytes
MeSH terms
Animals, Endoplasmic Reticulum, Humans, Lysophospholipids, Phosphatidic Acids, Phosphoric Diester Hydrolases, PPAR gamma, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review